Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors

被引:19
|
作者
Xu, Caihong [1 ]
Li, Renzhong [1 ]
Shewade, Hemant Deepak [2 ,3 ,4 ]
Jeyashree, Kathiresan [5 ]
Ruan, Yunzhou [1 ]
Zhang, Canyou [1 ]
Wang, Lixia [1 ]
Zhang, Hui [1 ]
机构
[1] China Ctr Dis Control CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China
[2] Int Union TB & Lung Dis, South East Asia Off, New Delhi, India
[3] Int Union TB & Lung Dis, Paris, France
[4] Karuna Trust, Bengaluru, India
[5] Velammal Med Coll Hosp & Res Inst, Madurai, Tamil Nadu, India
来源
PLOS ONE | 2019年 / 14卷 / 04期
关键词
RESISTANT TUBERCULOSIS; DIAGNOSIS; TIME;
D O I
10.1371/journal.pone.0214943
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background China's national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. Objective Under the Global Fund programmatic management of drug-resistant TB (2006-13), we assessed the attrition and delay in the pathway and the factors associated. Methods Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pretreatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. Results Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pretreatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion 'previously treated' and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion 'treatment after lost to follow up'. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion 'recurrent TB'. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion 'treatment after failure'. Conclusion The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda
    Komakech, Kevin
    Nakiyingi, Lydia
    Fred, Ashab
    Achan, Beatrice
    Joloba, Moses
    Kirenga, Bruce J.
    Ssengooba, Willy
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [22] Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda
    Kevin Komakech
    Lydia Nakiyingi
    Ashab Fred
    Beatrice Achan
    Moses Joloba
    Bruce J. Kirenga
    Willy Ssengooba
    BMC Infectious Diseases, 24
  • [23] Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016
    Bhering, Marcela
    Duarte, Raquel
    Kritski, Afranio
    PLOS ONE, 2019, 14 (11):
  • [24] Genetic variability of Mycobacterium tuberculosiscomplex in patients with no known risk factors for MDR-TB in the North-eastern part of Lima, Peru
    Francesca Barletta
    Larissa Otero
    Jimena Collantes
    Belisa Asto
    Bouke C de Jong
    Carlos Seas
    Leen Rigouts
    BMC Infectious Diseases, 13
  • [25] Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda
    Ssengooba, Willy
    de Dieu Iragena, Jean
    Komakech, Kevin
    Okello, Iginitius
    Nalunjogi, Joanitah
    Katagira, Winceslaus
    Kimuli, Ivan
    Adakun, Susan
    Joloba, Moses L.
    Torrea, Gabriela
    Kirenga, Bruce J.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [26] High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India (vol 17, 249, 2017)
    Shewade, Hemant Deepak
    Kokane, Arun M.
    Singh, Akash Ranjan
    Verma, Manoj
    Parmar, Malik
    Chauhan, Ashish
    Chahar, Sanjay Singh
    Tiwari, Manoj
    Khan, Sheeba Naz
    Gupta, Vivek
    Tripathy, Jaya Prasad
    Nagar, Mukesh
    Singh, Sanjai Kumar
    Mehra, Pradeep Kumar
    Kumar, Ajay M. V.
    BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [27] Genetic variability of Mycobacterium tuberculosis complex in patients with no known risk factors for MDR-TB in the North-eastern part of Lima, Peru
    Barletta, Francesca
    Otero, Larissa
    Collantes, Jimena
    Asto, Belisa
    de Jong, Bouke C.
    Seas, Carlos
    Rigouts, Leen
    BMC INFECTIOUS DISEASES, 2013, 13
  • [28] Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India
    Isaakidis, Petros
    Varghese, Bhanumati
    Mansoor, Homa
    Cox, Helen S.
    Ladomirska, Joanna
    Saranchuk, Peter
    Da Silva, Esdras
    Khan, Samsuddin
    Paryani, Roma
    Udwadia, Zarir
    Migliori, Giovanni Battista
    Sotgiu, Giovanni
    Reid, Tony
    PLOS ONE, 2012, 7 (07):
  • [29] Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus-2009-2010
    Skrahina, Alena
    Khaliaukin, Andrei
    Falzon, Dennis
    Rusovich, Valiantsin
    Dara, Masoud
    Shyrayeu, Aliaksandr
    Zhylevich, Liudmila
    Zignol, Matteo
    Hurevich, Hennadz
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [30] The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China
    Tang, Qin
    Ke, Hui
    Sun, Wen-wen
    Zhang, Shao-jun
    Fan, Lin
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 5275 - 5287